NCT00990639View on ClinicalTrials.gov

Effect of Candesartan in Alcoholic Liver Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

March 31, 2009

Conditions
Alcoholic Liver Disease
Interventions
DRUG

candesartan for hepatic fibrosis

"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"

Trial Locations (1)

220-701

Yonsei University Wonju College of Medicine Wonju Christian Hospital, Wŏnju

All Listed Sponsors
lead

Yonsei University

OTHER

NCT00990639 - Effect of Candesartan in Alcoholic Liver Fibrosis | Biotech Hunter | Biotech Hunter